Introduction {#Sec1}
============

Neuroinflammation is a prominent feature of the neuropathology of Alzheimer's disease (AD), in addition to β-amyloid (Aβ) plaques, tau-containing neurofibrillary tangles (NFT), and synaptic dysfunction followed by neurodegeneration \[[@CR1]\]. Emerging evidence indicates that neuroinflammation, mediated by activated glial cells, plays a fundamental role in the pathogenesis and neurodegeneration of AD \[[@CR1]\]. Brain inflammation either triggered by or proceeding other AD pathology sustains and likely contributes to the progressive neurodegeneration that characterizes AD \[[@CR2]\]. Defining the molecular and cellular mechanisms underlying neuroinflammation as well as the chemical mediators of the inflammatory cascade are critical for understanding how neuroinflammation contributes to AD pathogenesis.

In AD, neuroinflammation increases with disease progression and is primarily driven by glial cells, especially microglia. This pathophysiological inflammatory cascade is associated with increased production of pro-inflammatory cytokines and other key inflammatory mediators \[[@CR3], [@CR4]\], including interleukin-1β (IL-1β), a very potent pro-inflammatory cytokine \[[@CR5]--[@CR8]\]*.* Higher concentrations of IL-1β have been reported in cerebrospinal fluid and brain tissue of AD patients \[[@CR9]--[@CR11]\] and in microglia surrounding Aβ plaques \[[@CR12]\]. Sustained elevations of IL-1β have been postulated to play a key role in AD pathogenesis \[[@CR6], [@CR12]--[@CR14]\]. Active IL-1β (17kD) is produced from an inactive 31 kDa pro-IL-1β via cleavage by the active form of cysteine protease caspase-1, which is in turn produced by the inflammasome, a multicomponent protein complex consisting of pattern-recognition receptors (including NLRP3, nucleotide-binding domain and leucine-rich repeat-containing protein 3), ASC (apoptosis-associated speck-like protein containing a CARD) and caspase-1 \[[@CR15]\]. The elevations of IL-1β reported in the AD brain strongly suggest activation of the inflammasome \[[@CR16]\]. Supporting this, aggregated Aβ has been shown to activate the inflammasome via a CD36/TLR4/6-dependent mechanism \[[@CR17]\]. NLRP3 deficiency reduces amyloid deposition and rescues memory deficits in the APP/PS1 model of AD \[[@CR18]\]. Understanding the cellular mechanisms responsible for IL-1β production by microglia may facilitate the development of a disease-modifying AD therapeutic that reduces IL-1β-mediated immune signaling and associated neuroinflammation.

The apolipoprotein E4 (APOE4) allele is the most common and important genetic risk factor for late-onset sporadic AD \[[@CR19]--[@CR21]\]. In the periphery, apoE regulates lipid metabolism \[[@CR22], [@CR23]\]. ApoE is the major apolipoprotein in the brain and together with apolipoprotein J (apoJ) plays a major role in cholesterol metabolism and transport involving lipid efflux and lipid delivery \[[@CR23]--[@CR26]\]. ApoE in the brain is mainly produced by astrocytes and also by neurons after brain injury \[[@CR27]\]. Interestingly, Cantuti-Castelvetri and colleagues recently described a defect in cholesterol clearance in apoE-deficient phagocytes (including microglia) isolated from the brain after myelin damage \[[@CR28]\]. Nugent et al. also reported that apoE knockout glia demonstrates a defect in cholesterol transport and accumulate cellular cholesterol esters \[[@CR29]\]. Both studies suggest an important role for apoE in brain cholesterol metabolism and homeostasis. In AD, numerous studies have also shown that apoE functions as an important regulator of brain amyloid (amyloid β-peptide or Aβ) deposition and clearance (apoE2\>E3\>E4), which most likely accounts for one of the known mechanisms as to how APOE4 increase AD risk \[[@CR30]\]. Recently, several studies have shown that APOE4 is associated with increased innate immune reactivity and enhanced cytokine secretion in primary microglia and peripheral macrophages in various animal models as well as human subjects \[[@CR31]--[@CR42]\]. Our previous work showed a higher innate immune reactivity of apoE4-expressing microglia following LPS treatment and found that APOE4/4 genotype greatly influences tau-dependent neuroinflammation in a tau transgenic mouse model of neurodegeneration \[[@CR43]\]. Together, these data suggest that apoE4 may exert a "toxic" gain of function to promote microglia-mediated neuroinflammation and neurodegeneration in AD.

25-hydroxycholesterol (25-HC) is a potent oxysterol regulator of cholesterol biosynthesis \[[@CR44]--[@CR46]\]. It is converted from cholesterol by the oxidoreductase cholesterol 25-hydroxylase (CH25H) \[[@CR47], [@CR48]\], an enzyme highly expressed and induced primarily in peripheral macrophages and dendritic cells in response to inflammatory stimuli like LPS and interferon \[[@CR49], [@CR50]\]. Although CH25H deficiency does not cause defects in cholesterol homeostasis \[[@CR50], [@CR51]\], 25-HC appears to serve multiple functions to regulate both innate and adaptive immunity. It acts as either an anti- or pro-inflammatory regulator involved in protection from a viral infection, macrophage foam cell formation, immunoglobin IgA production, and cytokine production \[[@CR50]\]. CH25H is an interferon (IFN)-inducible gene in response to viral infection \[[@CR52]\]. To date, the function of CH25H and 25-HC in the central nervous system has not been well characterized. An association of CH25H with AD was first reported in a hippocampal microarray study of AD brain tissue \[[@CR53]\] and further suggested by an AlzGene meta-analysis for a sporadic AD population \[[@CR54]\] and other AD patient-based independent systematic analyses \[[@CR55]--[@CR57]\]. The upregulation of CH25H mRNA in affected brain regions in AD patients versus controls was first reported in a hippocampal microarray \[[@CR53]\]. The upregulation of CH25H expression has also been detected in the brain tissue of AD transgenic mice \[[@CR58]--[@CR60]\]. Recently, Ofengeim et al. found that the upregulation of CH25H expression in microglia in APP/PS1 mice depends on RIPK1, a death-domain containing Ser/Thr kinase mediating downstream signaling of type I TNFα receptors \[[@CR61]\]. Moreover, two recent studies have reported a phenotypic change of microglia in neurodegenerative diseases from homeostatic to disease-associated microglia (DAM) \[[@CR62], [@CR63]\]. In these studies, CH25H has been identified as one of the upregulated genes featured in the DAM subcluster, which is characterized by expression of typical microglial markers, Iba1, Cst3, and Hexb, and upregulation of genes involved in phagocytosis and lipid metabolism, including Apoe, Ctsd, Lpl, Tyrobp, and Trem2 (reviewed by Deczkowska, et al. 2018) \[[@CR64]\].

In the present study, we investigated whether 25-HC regulates the innate immune response of microglia or whether the APOE4 allele relative to the other common APOE alleles impacts the effects of 25-HC on microglial activation. Our results demonstrate that CH25H is upregulated in the AD brain and AD transgenic mouse brain. We further show that 25-HC is produced by activated primary microglia and augments IL-1β production stimulated by the TLR4 agonist LPS. Importantly microglia expressing apoE4 produce much greater amounts of 25-HC and IL-1β in response to LPS treatment compared to apoE2- or apoE3-expressing microglia. Remarkably, 25-HC also markedly potentiates LPS-mediated IL-1β secretion by apoE4-expressing microglia. The inhibition of inflammasome activity markedly reduces the augmentation of microglial IL-1β secretion by 25-HC. Our results suggest that 25-HC may function as an inflammatory mediator of the IL-1β-dependent inflammatory cascade in microglia and thus, may contribute to apoE4-dependent neuroinflammation and neurodegeneration in AD.

Materials and methods {#Sec2}
=====================

Animals {#Sec3}
-------

All experiments were conducted in accordance with relevant NIH guidelines and regulations related to the Care and Use of Laboratory Animals and human tissue. Animal procedures were performed according to protocols approved by the Research Animal Resource Center at Weill Cornell Medicine. The APPPS1-21 transgenic mouse model \[[@CR65]\] co-expressing human APP KM670/671NL and Presenilin-1 L166P under the control of a neuron-specific Thy1 promoter element was kindly provided by Dr. Mathias Jucker through an agreement with Koesler. These mice were intercrossed and maintained on a C57BL/6 J background. PS19 expressing human P301S tau under the control of PrP promotor were purchased from the Jackson laboratory (\#008169) and backcrossed and maintained on a C57BL/6 background. CH25H knockout mice \[[@CR66]\] were purchased from the Jackson laboratory (JAX stock \#016263) and maintained as homozygotes. Human APOE targeted replacement mice with the human APOE2, APOE3, or APOE4 coding sequences inserted behind the endogenous murine APOE promoter on a C57BL/6 J background were provided by P.M. Sullivan of Duke University \[[@CR67]--[@CR69]\]. APOE-/- mice were purchased from Taconic. P301S tau transgenic mice that are homozygous for human APOE2 (TE2), APOE3 (TE3), APOE4 (TE4), or with no expression of apoE (TEKO) (C57BL/6) were generated by the Holtzman laboratory at Washington University, St. Louis as described previously \[[@CR43]\]. TLR4 knockout mice were purchased from the Jackson laboratory (JAX stock \#029051) and maintained as homozygotes. All animals were maintained in a pathogen-free environment, and experiments on mice were conducted according to the protocol approved by the Weill Cornell Medicine Animal Care Committee.

Human brain specimens {#Sec4}
---------------------

Frontal cortical tissue samples from AD patients or age-matched controls with no reported clinical signs of dementia (≥80 years) were obtained from the Brain Bank of the University of Miami Miller School of Medicine, the Human Brain and Spinal Fluid Resource Center of the Greater Los Angeles VA Healthcare System at the West Los Angeles Healthcare Center, University of Maryland Brain and Tissue Bank, and the New York Brain Bank at Columbia University through requests from the NIH NeuroBioBank. All procedures were approved by the Weill Cornell Medicine Human Biology Research Ethics Committee.

Culture and treatment of primary microglia {#Sec5}
------------------------------------------

Primary neonatal microglia were prepared from cerebral cortices of 1--3 day old neonatal mice as previously described \[[@CR70]\]. Cell suspensions of cerebral cortices were seeded into a 75-ml flask and cultured in DMEM/F12 medium containing 10% FBS and 5 ng/ml GM-CSF. Microglial cells floating on top of the astrocyte layer were harvested at 12 DIV by shaking for 2 h at 200 rpm and seeded onto 48 well (3 × 10^5^/well) or 24 well (6 × 10^5^/well) culture plate in DMEM/ F12/10%FBS medium without GM-CSF. Over 98% of the cells were determined to be microglia (Iba-1 positive) by immunohistochemistry. After seeding for 24 h, cells were washed once with serum-free medium and treated with various reagents in serum-free DMEM/F12 medium supplemented with 0.02% BSA. The reagents used in microglia treatment were LPS (Sigma, L5293, Escherichia coli, 0111:B4); ATP (sigma A2383); 25-hydroxycholesterol (Avanti\#700019 or Sigma H1015); cholesterol (Avanti\#700100); 7 α-hydroxycholesterol (Avanti\#700034); VX-765 (Medchemexpress). Ent-25-hydroxycholesterol was synthesized as described \[[@CR71]\].

Cytokine ELISAs {#Sec6}
---------------

Supernatants from cell cultures were collected and the concentrations of IL-1β (BioLegend\#432601), IL-1α (Biolegend\#433401), IL-6 (Bon Opus Biosciences\#BE010059B), and TNFα (Biolegend\#430901) were determined by ELISA according to the manufacturer's instructions. All cytokine levels were normalized to microglial protein levels determined by BCA assay.

ASC speck analysis {#Sec7}
------------------

For measuring ASC speck formation, mouse primary microglia were seeded at 0.15 × 10^6^/well in 8-well chamber Millicell EZ slides (Millipore PEZGS0816) and allowed to attach overnight. The following day, the cells were treated with 100 ng/ml LPS in the presence or absence of 10 μg/ml 25-HC over 16 h. The cells were fixed in 4% paraformaldehyde and then washed three times in PBS with Tween 20 (PBST). After permeabilization with Triton X-100 and blocking with 10% bovine serum albumin in PBS, the cells were incubated with anti-mouse ASC antibody (Cell Signaling\#67824) overnight at 4 °C. After washing with PBST, the cells were incubated with secondary antibodies (Jackson ImmunoResearch) in PBS for 30 min and rinsed in PBST. The slides were mounted with a mounting solution containing DAPI. Images were taken using a Nikon Eclipse 80i microscope. For each treatment condition, 3--5 pictures taken from different areas in the well at 20× magnification were used for counting cells containing ASC speck. The total number of cells was determined by visualizing DAPI positive nuclei. Each experimental condition was repeated more than three times.

Immunoblotting {#Sec8}
--------------

To detect CH25H protein, microsomal membranes were prepared as described previously \[[@CR66], [@CR72]\], solubilized in a small volume of buffer A (50 mM Tris-Cl, pH 7.4, 1 mM EDTA, 0.05% (w/v) SDS), mixed with an equal amount of HMG-CoA solubilization buffer (62.5 mM Tris-Cl, pH 6.8, 15% SDS, 8 M urea, 10% glycerol, 100 mM dithiothreitol). A total of 100 μg lysate was incubated with NuPAGE LDS sample buffer at 37 °C for 20 min followed with separation by NuPAGE 4-12% Bis-Tris gel and transferring to nitrocellulose membrane (Amersham Biosciences). For other proteins, cell lysates (\~40 μg of protein/lane) were resolved in 4-20% Bis-Tris gels and transferred to nitrocellulose membranes. Blots were incubated with antibodies at 4 °C overnight followed by horseradish peroxidase-coupled secondary antibodies and ECL developing kits (Amersham Biosciences). The images were taken using Bio-Rad Molecular-Imager ChemiDoc XRS+ and densitometry of the bands was measured with Bio-Rad Image lab software and all values were normalized to β-actin or glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Antibodies used for immunoblotting were mouse anti-human CH25H (hybridoma supernatant, neat, kindly provided by Dr. David Russell, University of Texas, Southwestern medical center) \[[@CR66]\], mouse anti-GAPDH antibody (GeneTex, GT239), mouse-anti-β-actin (GeneTex, GT5512), mouse anti-human 6E10 for full length APP (Covance, SIG393206), rabbit anti-mouse ASC antibody (Cell Signaling\#67824), mouse anti-NLRP3 (AdipoGen, Cryo2, AG-20B-0014-C100), mouse anti-GM130 (Santa Cruz, sc-55591), rabbit anti-IL-1β (Abcam, ab9722).

Quantification of 25-hydroxycholesterol {#Sec9}
---------------------------------------

Primary microglia were prepared and treated as described above. Media were collected and frozen at −80 °C after removing floating cells. For each sample, 5 μL of methanol or 5 μL of deuterated internal standard at a concentration of 500 ng/mL were added to 50 μL of microglia growth media separately before being mixed and then hydrolyzed using 1 N KOH at 90 °C for 2 h. The samples were then liquid-liquid extracted with methyl tert-butyl ether and the organic phase evaporated to dryness under air at 50 °C. Sample residues were reconstituted in 100 μL of 80% methanol. Reconstituted samples (5 μl) were then injected onto an Eksigent microLC 200 system. The separation was effected with a Waters Acquity 1 mm × 50 mm C18 reverse-phase column at 50 μL/min over 7 min. Data were acquired by an ABSciex QTRAP 5500 mass spectrometer using the Turbo Spray source maintained at 300 °C. Spray voltage was maintained at 4000 volts, curtain gas at 40 L/min, gas 1 at 30 L/min, and gas 2 at 30 L/min. Chromatographic peak areas of transition 385.4/367.4 (CE = 25 V, DP = 60 V) were integrated and quantified using MultiQuant 3.0 software (ABSciex).

RNA isolation, real-time RT-PCR and nanostring analysis {#Sec10}
-------------------------------------------------------

Total RNA was isolated from primary microglia or mouse brain tissue with the PureLink RNA mini kit (Invitrogen\#12183018A) and reverse transcribed to cDNA using SuperScript IV VILO Master Mix with ezDNase Enzyme (Thermo Fisher, \# 11766050) following the manufacturer's protocol. Quantitative real-time PCR was performed using Taqman gene expression assays and gene expression master mix (Applied Biosystems, \#4369016). The changes in gene expression were normalized to β-actin or glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

Statistical analysis {#Sec11}
--------------------

Data are expressed as mean ± SEM. Significance was assessed with Student's *t* test, one-way or two-way ANOVA followed by Tukey multiple comparisons test or Bonferroni's post hoc test using Prism version 8.0 software (GraphPad).

Results {#Sec12}
=======

CH25H is upregulated in human AD brain and AD-related transgenic mouse brain {#Sec13}
----------------------------------------------------------------------------

We first examined the expression of CH25H in postmortem human AD brain tissue. Using quantitative PCR, we observed that the level of CH25H mRNA was significantly upregulated in frontal cortical tissue of the AD brain (*n* = 14) compared to age-matched (non-AD) controls (*n* = 9, *p* \< 0.05) (Fig. [1](#Fig1){ref-type="fig"}a, all subjects were age \> 80 and both genders were included). The protein level of CH25H was also increased in AD brain tissue as detected by Western blot using a CH25H antibody (Fig. [1](#Fig1){ref-type="fig"}b). The increased levels of CH25H mRNA and protein were also observed in the frontal cortex of 4-month-old APPPS1-21 mice bearing amyloid plaques \[[@CR65]\] (Fig. [1](#Fig1){ref-type="fig"}c, d, e). We further examined the expression of CH25H in PS19 mice expressing the pathogenic human P301S tau mutation at 9 months of age bearing massive tau pathology, inflammation, and neurodegeneration in the brain \[[@CR73]\]. Compared to their age-matched non-tg littermates, we detected an increase of CH25H mRNA in the brain of PS19 tg mice (Fig. [1](#Fig1){ref-type="fig"}f). Moreover, when we measured CH25H mRNA levels in the frontal cortex of P301S tau transgenic mice that are homozygous for human APOE2 (TE2), APOE3 (TE3), APOE4 (TE4) or with no expression of apoe (TEKO) using nanostring analysis, we found that TE4 mice, an aggressive mouse model showing the strongest brain neurodegeneration and neuroinflammation \[[@CR43]\], express significantly higher levels of CH25H mRNA than TEKO mice (Fig. [1](#Fig1){ref-type="fig"} g). Together, these data suggest that CH25H expression is upregulated in the human AD brain and mouse brain when there is prominent amyloid or tau pathology and neuroinflammation. Fig. 1CH25H expression is increased in AD brain and AD transgenic mouse brain bearing amyloid or tau pathology. **a**, **b** Expression of CH25H at mRNA (**a**) or protein (**b**) levels in the brain tissue of AD patients vs age-matched non-demented controls. CH25H protein levels were normalized by β-actin with *p = 0.06* (statistically analyzed using unpaired Student *t* test). **c**, **d** Expression of CH25H at mRNA (**c**) or protein (**d**) in APPPS1 transgenic mouse brain vs. age-matched non-tg littermates. **e** Quantification of d showing protein levels for CH25H, ASC, and NLRP3 by normalization to β-actin. **f** Expression of CH25H mRNA in PS19 tau P301S transgenic mouse brain vs non-tg littermates. **g** Expression of CH25H mRNA in TE2, TE3, TE4, and TEKO mouse brain. Statistical significance was determined by Student *t* test with *\*p \<* 0.05, *\*\*p \<* 0.01 or \*\*\**p \<* 0.005 in **a**, **c**, **e**, and f, or by ordinary one-way *ANOVA* with Dunnett's multiple comparisons test \**\*p* \< 0.01 in **g**

LPS stimulates 25-HC production and CH25H expression in primary microglia {#Sec14}
-------------------------------------------------------------------------

In macrophages, the TLR4 agonist lipopolysaccharide (LPS) stimulates expression of CH25H and production of 25-HC \[[@CR49]\]. In the central nervous system, CH25H is mainly expressed in microglia, the counterpart of peripheral macrophages, with very limited expression, if any, in other brain cell types, based on the Stanford transcriptome database generated by the Barres group (<http://www.brainrnaseq.org>) (Supplemental Fig. [1](#MOESM1){ref-type="media"}a). To explore a potential role for CH25H and its oxysterol product 25-HC in microglia-mediated innate immunity, we first measured 25-HC production by LC/MS in cultured microglia isolated from the brain tissue of neonatal wild type mice in response to stimulation by LPS. A time- and dose-dependent increase of 25-HC production was observed in the cell lysate and medium of LPS-treated microglia compared to untreated microglia (Fig. [2](#Fig2){ref-type="fig"}a, b). As measured by qPCR, LPS stimulated the expression of the pro-inflammatory cytokines IL-1β and TNFα as well as inflammasome genes such as NLRP3. It also potently upregulated CH25H mRNA in microglia (≥50-fold) (Fig. [2](#Fig2){ref-type="fig"}c). The increase in CH25H expression induced by LPS was further confirmed by Western blot using a CH25H specific antibody (Fig. [2](#Fig2){ref-type="fig"}c, insert). We next evaluated the effects of LPS on CH25H expression in the mouse in vivo. When wild type mice were treated with LPS (8.2 mg/kg via i.p.) for 24 h, a marked increase in CH25H mRNA was detected in the hippocampus and cerebral cortex of LPS-treated mice compared to vehicle-treated mice (Fig. [2](#Fig2){ref-type="fig"}d). In contrast, the expression of CYP27a1 or CYP7b1 (two other enzymes involved in the cholesterol:oxysterol metabolic pathway) was not influenced by LPS treatment (Fig. [2](#Fig2){ref-type="fig"}d), suggesting that the induction of CH25H by LPS was highly specific. These results demonstrate that the production of 25-HC and the expression of CH25H are highly responsive to TLR4 stimulation in cultured primary microglia as well as in mouse brain in vivo. Fig. 2LPS stimulates 25HC production and CH25H expression in primary microglia and in mouse brain. **a** LPS stimulates 25-HC production and secretion in primary microglia in a time- and dose-dependent manner. Primary microglia were treated with LPS (0, 10, and 100 ng/ml) for 6 and 24 h. The levels of 25-HC in cells (**a**) and media (**b**) were determined by GC-MS. *\*\*\*\*p \<* 0.001 by ordinary one-way *ANOVA*. **c** LPS induces the expression of CH25H, IL-1β, TNFα, and NLRP3 inflammasome mRNA in primary microglia. The comparative gene expressions were determined by qPCR using RNA extracted from primary microglia with or without 10 ng/ml LPS treatment for 24 h. Insert: CH25H protein level in CH25H+/+ or CH25H-/- primary microglia treated with or without 10 ng/ml LPS. It is a representative result of two independent experiments. **d** Gene expression analysis of CH25H, IL-1β, TNFα, Cyp7b, and Cyp27a1 in brain tissue of C57BL6 mice treated with 8.2 mg/kg LPS (*n* = 3) for 24 h as determined by qPCR. \**p* \< 0.05,*\*\*p* \< 0.01, *\*\*\*p* \< 0.005 by Student *t* test comparing LPS-treated mouse brain to saline-treated control brain

Depletion of 25-HC selectively attenuates LPS-induced IL-1β expression in primary microglia {#Sec15}
-------------------------------------------------------------------------------------------

To examine whether 25-HC is involved in the inflammatory response of microglia, we eliminated 25-HC production using microglia prepared from CH25H knockout (KO) mice (Supplementary Fig. [1](#MOESM1){ref-type="media"}b). When WT or CH25H KO microglia were treated with LPS, we observed a significant reduction in the level of IL-1β secreted into the medium of CH25H KO microglia compared to WT microglia (Fig. [3](#Fig3){ref-type="fig"}a). The levels of IL-1α, a cytokine often co-released with IL-1β, were also reduced (Fig. [3](#Fig3){ref-type="fig"}b). In contrast, the production of TNFα (Fig. [3](#Fig3){ref-type="fig"}c) or IL-6 (not shown) were similar in both WT and CH25H KO cells treated with LPS. The addition of 25-HC to CH25H KO microglia fully rescued the attenuated IL-1β/α production observed in CH25H KO microglia to a comparable level as WT microglia (Fig. [3](#Fig3){ref-type="fig"}d). These data suggest that 25-HC contributes to the LPS-triggered IL-1β production by microglia. To directly evaluate the effect of 25-HC on IL-1β/α production, we treated WT microglia with 25-HC alone or in combination with LPS. Compared to LPS treatment alone, the addition of 25-HC in the presence of LPS resulted in a marked dose-dependent increase of microglial IL-1β and IL-1α secretion while 25-HC treatment alone had no effect (Fig. [3](#Fig3){ref-type="fig"}e). Fig. 325-HC selectively amplifies LPS-induced IL-1β expression and secretion. **a**-**c** WT and CH25H KO primary microglia were treated with LPS (0, 0.1, 1, 10, 100 ng/ml) for 24 h. The levels of secreted IL-1β (**a**), IL-1α (**b**), and TNFα (c) in the medium were measured by ELISA. **d** The levels of secreted IL1β from WT and CH25H KO microglia treated with LPS (10 ng/ml) with or without 25-HC (10μg/ml) were measured by ELISA. **e** Primary microglia were treated with 10 ng/ml LPS in the presence of different concentrations of 25-HC for 24 h. The levels of IL-1β in the media were determined by ELISA and (**f**) the levels of intracellular pro-IL1β and mature IL1β secreted in the media as measured by Western blotting. Statistical analyses were determined by multiple *t* test in **a**, **b**, **c**, **d**; one-way ANOVA in **e**. \**p* \< 0.05*, \*\*p* \< 0.01, *\*\*\*p* \< 0.005, *\*\*\*\*p* \< 0.001. The data shown are representative of three or more independent experiments

Mature IL-1β (17 kDa) is produced from its 31 kDa pro-IL-1β by the action of the protease caspase-1, which is in turn produced by the inflammasome complex; the mature cytokine is then rapidly secreted into the medium. We next examined the effects of 25-HC on the level of pro-IL-1β protein remaining in cells and mature IL-1β protein released into the medium by Western blotting. LPS treatment markedly increased the cellular level of pro-IL-1β as well as the inflammasome proteins NLRP3 and ASC1, resulting in a limited amount of 17 kDa IL-1β produced and secreted into the medium. However, the addition of 25-HC markedly and dose-dependently stimulated the release of active 17 kDa IL-1β into the medium (Fig. [3](#Fig3){ref-type="fig"}f). The intracellular protein levels of unprocessed pro-IL-1β, NLRP3, or ASC were not influenced by the presence of 25-HC (Fig. [3](#Fig3){ref-type="fig"}f). Therefore, 25-HC may regulate IL-1β production at a posttranslational level. Together, these results suggest that 25-HC modulates LPS-activated inflammatory responses by selectively promoting mature IL-1β production.

APOE4-expressing microglia show exaggerated IL-1β production in response to LPS and 25-HC treatment {#Sec16}
---------------------------------------------------------------------------------------------------

Previous studies have shown that APOE isoforms differentially influence the innate immune response of microglia \[[@CR32], [@CR33]\]. We, therefore, examined the effects of the common APOE isoforms on both LPS and 25-HC-enhanced production of IL-1β in microglia. Microglia were prepared from neonatal mice expressing human APOE2 (E2), APOE3 (E3), or APOE4 (E4) at the mouse APOE locus \[[@CR67]--[@CR69]\]. Consistent with previous reports, E4-expressing microglia produced higher levels of IL-1β than E2-expressing cells or APOE deficient cells (EKO) after 6 h (Fig. [4](#Fig4){ref-type="fig"}a) or 24 h (Fig. [4](#Fig4){ref-type="fig"}b) following LPS treatment alone. As expected, 25-HC dose-dependently increased IL-1β production at 6 h (Fig. [4](#Fig4){ref-type="fig"}a) and at 24 h (Fig. [4](#Fig4){ref-type="fig"}b). Strikingly, co-incubation with 25-HC resulted in a marked potentiation of IL-1β production in E4-expressing microglia compared to E2-expressing or EKO microglia at each concentration of 25-HC tested (Fig. [4](#Fig4){ref-type="fig"}a and b), resulting in significantly higher levels of IL-1β production from E4 microglia than that from E2 or EKO microglia (Fig. [4](#Fig4){ref-type="fig"}a and b). Although LPS induced greater IL-6 production in E4-expressing microglia, 25-HC treatment did not influence the production of IL-6 (Fig. [4](#Fig4){ref-type="fig"}c). We further compared the IL-1β-inducing activity of 25-HC between E4 and E3 microglia. A higher amount of secreted (extracellular) IL-1β was observed in E4 microglia than in E3 microglia treated with both LPS and 25-HC (Fig. [4](#Fig4){ref-type="fig"}d). Consistently, we detected more mature IL-1β protein (17kd) in the medium of E4 microglia than in the medium of E3 microglia, while the levels of intracellular pro-IL-1β did not increase in cells treated with 25-HC (Fig. [4](#Fig4){ref-type="fig"}e). Together, these data demonstrate that apoE isoforms differentially influence the ability of 25-HC to augment the secretion of IL-1β production in LPS-activated microglia and the presence of APOE4 markedly augments the effects of 25-HC in promoting IL-1β production, shifting the dose-response for 25-HC substantially to the left. Lastly, the production of 25-HC by E2 or E4-expressing microglia was measured. We found that E4 microglia produced a greater amount of 25-HC measured in both cells and medium than E2 microglia when treated with LPS (Fig. [4](#Fig4){ref-type="fig"}f). Fig. 4Exaggerated IL-1β and 25-HC production in LPS-activated microglia expressing human ApoE4. The levels of IL-1β or IL-6 secreted into the medium in apoE2- or apoE4-expressing microglia or apoE KO microglia treated with LPS (10 ng/ml) and 25-HC (0, 1, 2, or 10 μg/ml) for 6 h (**a**) or 24 h (**b** and **c**). The levels of IL-1β secreted in the medium of apoE3- or apoE4-expressing microglia after 24 h treatment with LPS (10 ng/ml) and 25-HC (10 μg/ml) (**d**, **e**) and the levels of 25-HC in these cells or medium were determined by GC-MS (**f**). Statistical significances were determined by two-way ANOVA with multiple comparisons in **a**, **b**, **c**, **d**, or unpaired Student *t* test in **f**. \**p* \< 0.05, *\*\*p* \< 0.01, *\*\*\*p* \< 0.005, *\*\*\*\*p* \< 0.001*,* respectively. The data shown are representative of three or more independent experiments

Augmentation of LPS-induced IL-1β induction by 25-HC is enantioselective {#Sec17}
------------------------------------------------------------------------

To examine the specificity of 25-HC, we first tested the effects of both the 25-HC precursor cholesterol and another cholesterol metabolite 7α-HC on IL-1β production. Comparing to the promoting effects of 25-HC on IL-1β/α production, coincubation of cholesterol or 7α-HC with LPS at a similar concentration as 25-HC did not promote LPS-induced IL-1β/α production in microglia (Fig. [5](#Fig5){ref-type="fig"}a, b, c). We further evaluated the IL-1β-inducing activity of *ent*-25-HC, the inactive enantiomer of 25-HC \[[@CR74]\], and found that *ent*-25HC exhibited only very weak IL-1β-inducing activity and was at least an order of magnitude less potent than 25-HC (Fig. [5](#Fig5){ref-type="fig"}d). These results demonstrate that the IL-1β induction by 25-HC is enantioselective and thus likely mediated via a specific protein target(s). Fig. 5IL-1β/α induction by 25-HC is highly specific. The levels of secreted IL-1β (**a**), IL-1α (**b**), or IL-6 (**c**) in the medium of primary microglia treated with LPS (10 ng/ml) in the presence of 25-HC (10 μg/ml), cholesterol (10μg/ml), or 7α-HC (10 μg/ml) for 24 h. **d** Ent-25-HC (10 μg/ml) has much weaker effects in augmenting IL-1β production in primary microglia treated with LPS (10 ng/ml) for 24 h. The levels of cytokines were determined by ELISA. Statistical significances were determined by ordinary two-way ANOVA with Tukey multiple comparisons test. \**p* \< 0.05, *\*\*p* \< 0.01, *\*\*\*p* \< 0.005, *\*\*\*\*p* \< 0.001. The data shown are representative of two or more independent experiments

25-HC induces IL-1β via activation of caspase-1 and the inflammasome {#Sec18}
--------------------------------------------------------------------

Active 17kD IL-1β is produced from pro-IL-1β after proteolytic cleavage by caspase-1. Formation of Adaptor protein apoptosis-associated Speck-like protein with a CARD (ASC), recognized as large perinuclear cellular aggregates, is a hallmark of inflammasome activation that correlates with caspase-1 cleavage and release of mature IL-1β \[[@CR75]\]. To further address if 25-HC activates the inflammasome in microglia, we compared the number of cells containing ASC speck in microglia treated with LPS alone or LPS combined with 25-HC. The number of ASC speck-containing cells significantly increased following treatment with LPS and 25-HC compared to LPS alone (Fig. [6](#Fig6){ref-type="fig"}a). 25-HC treatment alone, however, did not induce ASC speck formation (Fig. [6](#Fig6){ref-type="fig"}a, b). We further found that the induction of ASC speck by LPS and 25-HC is dependent on TLR4 because no ASC speck formation was detected in TLR4 KO microglia treated with LPS and 25-HC (Fig. [6](#Fig6){ref-type="fig"}c, d). The induction of IL-1β by LPS and 25-HC was also markedly reduced or eliminated in TLR4 KO microglia (Fig. [6](#Fig6){ref-type="fig"}c, d). These data suggest that 25-HC augments IL-1β secretion via activation of the inflammasome in a TLR4-dependent manner. Fig. 625-HC induces inflammasome activation. ASC specks in microglia treated with LPS (10 ng/ml) without or with 25-HC (10 μg/ml) were stained by ASC antibody (green) and DAPI for nuclei (blue) (**a**). Quantification of ASC specks in microglia treated with medium alone (ctl), medium-containing LPS (10 ng/ml), 25-HC (10μg/ml), or LPS (10 ng/ml) plus 25-HC (10 μg/ml) (**b**). WT or TLR4 deficient microglia were treated with LPS (10 ng/ml) and 25-HC (10 μg/ml) for 24 h followed by ASC antibody staining (green) and DAPI (blue) (**c**) or ELISA measurements of secreted IL1β (**d**). Inhibition of caspase 1 by VX765 (**e**) or a high concentration of potassium (50 mM) (**f**) in the medium prevents 25-HC-dependent IL-1β production in microglia treated with 10 ng/ml LPS for 24 h. Statistical analyses were determined by ordinary two-way ANOVA with Tukey multiple comparisons test in **c**, **e** and **f** or Student *t* test in **d**. \**p* \< 0.05*, \*\*p* \< 0.01, *\*\*\*p* \< 0.005*, \*\*\*\*p* \< 0.001*.* The data shown are representative of three or more independent experiments

Activation of the inflammasome, such as NLRP3, triggers oligomerization and activation of caspase-1 that cleaves pro-IL-1β to biologically active IL-1β. To examine if the induction of IL-1β by 25-HC is caspase-1-dependent, primary microglia were treated with LPS and 25-HC in the presence of VX765, a cell-penetrant prodrug of VRT-043198 that selectively inhibits the caspase-1 subfamily of cysteine proteases \[[@CR76]\]. Treatment with VX765 completely inhibited the effect of 25-HC on IL-1β production (Fig. [6](#Fig6){ref-type="fig"}e), suggesting that 25-HC induces IL-1β production by activating the inflammasome and caspase-1.

Potassium efflux is one of the common mediators of inflammasome activation in response to diverse stimuli \[[@CR15]\]. When potassium efflux was blocked by a high concentration of extracellular KCl, we found that the induction of IL-1β by LPS and 25-HC was effectively prevented by 50 mM KCl (Fig. [6](#Fig6){ref-type="fig"}f). This result confirms that activation of the inflammasome by LPS is augmented by 25-HC and further suggests that 25-HC regulates IL-1β induction upstream of potassium efflux.

Discussion {#Sec19}
==========

CH25H and 25-HC in innate immunity {#Sec20}
----------------------------------

25-hydroxycholesterol (25-HC) is an enzymatically derived oxidation product of cholesterol, which is produced primarily by circulating and tissue-resident macrophages and which has been reported to have both anti-inflammatory as well as pro-inflammatory effects in various model systems of innate immunity \[[@CR50]\]. The enzyme cholesterol-25-hydroxylase (CH25H), which catalyzes the synthesis of 25-HC from cholesterol is markedly upregulated in macrophages following stimulation with interferon and the TLR4 ligand, LPS \[[@CR49]\]. 25-HC has also been reported to regulate cholesterol metabolism by suppressing cholesterol biosynthesis via SREBP processing and facilitating reverse cholesterol transport via activation of liver X receptors (LXRs) and various downstream genes \[[@CR77]\]. 25-HC has been shown to be a potent antiviral oxysterol and likely mediates the antiviral action of interferons against a variety of enveloped DNA and RNA viruses \[[@CR50], [@CR78]\]. Although 25-HC's anti-inflammatory actions have been widely documented (see below), its pro-inflammatory effects have also been reported by multiple groups. Rosklint and colleagues \[[@CR79]\] first demonstrated that 25-HC, even at very low concentrations, increased IL-1β mRNA expression and secretion following LPS challenge in human monocyte-derived macrophages, a finding reminiscent of our data in primary murine microglia. Several subsequent studies have also reported pro-inflammatory effects of 25-HC in peripheral macrophages. For example, Gold et al. reported that 25-HC acts as an amplifier of inflammation in macrophages via an AP-1-mediated mechanism, contributing to the tissue damage in mice following influenza infection \[[@CR80]\]. CH25H deficient mice have also been shown to have decreased inflammatory-mediated pathology and death following influenza infection \[[@CR80]\], reduced immune responses both following experimental autoimmune encephalomyelitis (EAE) \[[@CR81]\] and in a mouse model of X-linked adrenoleukodystrophy (X-ALD) \[[@CR82]\], again supporting a pro-inflammatory and potentially "toxic" function of 25-HC in inflammatory and neurodegenerative disorders. Moreover, 25-HC was recently identified as an integrin ligand and shown to directly induce a pro-inflammatory response in macrophages \[[@CR83]\]. Finally, following our submission, Russo et al. have very recently shown that 25-HC is required for the obesity-induced expression of pro-inflammatory genes (including IL-1β) in adipose tissue macrophages (ATMs) as well as in bone marrow-derived macrophages \[[@CR84]\]. These observations clearly suggest pro-inflammatory actions of 25-HC in response to immune stimuli in macrophages such as we have observed in microglia. It is not uncommon to see such dual actions of various immune modulators. For example, some pro-inflammatory cytokines and chemokines (such as IFN-γ, IL-2, CCL2, and CXCL12) may act as anti-inflammatory mediators, while the anti-inflammatory mediator TGF-β can become pro-inflammatory under certain conditions \[[@CR85]\]. Such a dual action of certain immune modulators could prepare the immune system to respond to a stressor (pro-inflammatory effects) and subsequently restore homeostasis (anti-inflammatory effects) as proposed by Cruz-Topete and Cidlowski for glucocorticoids \[[@CR86]\]. Nonetheless, collectively, these observations of both anti- and pro-inflammatory effects of 25-HC, including our current study, strongly suggest that 25-HC may serve as an important mediator of the innate immune response in the brain.

In our study, we show that CH25H is expressed in microglia in vitro and further demonstrate that the TLR4 agonist LPS induces a marked upregulation of CH25H expression and 25-HC production and secretion. This increase in CH25H expression and 25-HC production in microglia was accompanied by corresponding increases in the secretion of the inflammatory cytokines IL-1β, IL-1α, and TNFα. Reductions in both LPS-stimulated IL-1β and IL-1α secretion (but not TNFα secretion) were observed in CH25H-deficient microglia, suggesting an autocrine or paracrine effect of 25-HC in amplifying pro-inflammatory signaling involving IL-1β/α in microglia (see below). Treatment of CH25H-deficient microglia with 25-HC restored the effect of LPS on IL-1β/α secretion. We also observed an increase in CH25H mRNA following LPS treatment of wild-type mice in vivo, consistent with the in vitro microglia data.

Possible roles of CH25H and 25-HC in Alzheimer's disease {#Sec21}
--------------------------------------------------------

CH25H is located on chromosome 10q23, a region strongly linked to AD \[[@CR54]\]. In a large scale AlzGene meta-analysis including 1282 AD patients and 1312 controls from five independent populations (French, Russian, USA, Swiss, Mediterranean), a significant association of rs13500 'T' allele and haplotypes in the CH25H promoter was previously reported to be associated with the risk of developing AD and with different rates of Aβ/amyloid deposition \[[@CR54]\]. However, the association of this rs13500 CH25H promoter polymorphism was not found in two subsequent studies \[[@CR87], [@CR88]\] nor has an association between CH25H and AD risk be observed in several large GWA studies, making this association "suggestive" at best \[[@CR89]--[@CR91]\]. More recently, several genome-wide expression studies carried out in models of accelerated aging, AD pathology and neuroinflammation have all identified CH25H as being significantly upregulated in the brain \[[@CR58]--[@CR60]\]. Ofengeim et al. found that the upregulation of microglial CH25H expression in APP/PS1 mice depends on RIPK1, a death-domain containing Ser/Thr kinase-mediating downstream signaling of type I TNFα receptor \[[@CR61]\]. Here, we also show that CH25H is upregulated in AD brain tissue compared to age-matched controls as well as in three mouse models of AD pathology; APP/PS1 transgenic mice, tau transgenic mice (PS19) and a recently described APOE4xP301S (TE4) tau transgenic mouse model of accelerated tau pathology and neurodegeneration \[[@CR43]\]. Finally, it is important to underscore that CH25H has been shown to be upregulated in a specific subset of microglial genes associated with neurodegeneration, called disease-associated microglia (DAM), in several neurodegenerative disease models (see Supplementary Fig. [2](#MOESM1){ref-type="media"}a) based on the public database published by Friedman et al. 2018 \[[@CR92]\]. Recently, a list of signature genes upregulated in a phagocytic microglia subset (neurodegeneration-associated, or DAM) reported by Krasemann et al. also include CH25H, whose upregulation is partially dependent on the presence of apoE (Supplementary Fig. [2](#MOESM1){ref-type="media"}b) \[[@CR63]\]. Moreover, an increased (\>3-fold) expression of CH25H was reported in the DAM gene dataset reported by Keren-Shaul and colleagues \[[@CR62]\]. These findings suggest that 25-HC may be involved in AD pathogenesis, especially given its reported pro-inflammatory properties and our data on its marked potentiation of cytokine expression and secretion from microglia stimulated by the TRL4 agonist, LPS.

CH25H, 25-HC, and APOE genotype {#Sec22}
-------------------------------

Given the important role of APOE4 as a genetic risk factor for AD and its reported role in regulating innate immunity in the brain \[[@CR93]\], we examined whether CH25H expression and 25-HC production in microglia were affected by APOE genotype. First, we found that apoE4-expressing microglia produced significantly more 25-HC in response to LPS treatment than apoE2-expressing microglia. We also found that apoE4-expressing microglia produced more IL-1β and IL-6 in response to LPS treatment as has been previously reported \[[@CR33]\]. To our surprise, co-incubation of 25-HC with LPS significantly augmented IL-1β production in apoE4-expressing microglia compared to either apoE2-expressing microglia or apoE-deficient (knockout) microglia, markedly shifting the dose-response curve for 25-HC to the left. In fact, relatively low concentrations of 25-HC (≤2.5 μM) stimulated IL-1β production in apoE4-expressing (vs. apoE2-expressing) microglia, again demonstrating that 25-HC's pro-inflammatory effects in this in vitro model of innate immunity are APOE isoform-dependent. Previous work has shown that compared with APOE3 homozygotes \[[@CR32]\], treatment with LPS induces higher levels of various cytokines (including IL-1β) in the serum of human APOE4 carriers and in the brains of apoE4-expressing targeted replacement mice \[[@CR33]\]. In vitro, apoE4-expressing microglia exhibit higher "innate immune reactivity" following LPS treatment measured by both cytokine and NO production \[[@CR33]\]. Moreover, APOE genotype alters glial activation in response to LPS treatment \[[@CR94]\]. Together with our in vivo data in several AD mouse models demonstrating higher brain levels of microglial and brain CH25H mRNA, we hypothesize that 25-HC may be an important pro-inflammatory chemical messenger whose production and secretion will greatly amplify cytokine secretion in apoE4-expressing microglia in a paracrine or autocrine manner (Supplementary Fig. [3](#MOESM1){ref-type="media"}), and may thus contribute either indirectly or even directly to the neuroinflammation and neurodegeneration that characterize AD. In this regard, Jang and colleagues \[[@CR82]\] have recently shown that 25-HC has pro-inflammatory actions in a study of X-linked adrenoleukodystrophy (X-ALD), a progressive neurodegenerative disorder characterized by the accumulation of very long-chain fatty acids. They observed that 25-HC is markedly increased in X-ALD brain tissue, promotes IL-1β production and neuroinflammation, and is directly neurotoxic when administrated to the brain in vivo \[[@CR82]\].

Both 25-HC and apoE are also important regulators of lipid metabolism \[[@CR95]\]. 25-HC regulates cholesterol efflux, sterol synthesis, fatty acid synthesis, and sphingolipid metabolism \[[@CR96]\]. 25-HC has also been found to regulate lipid homeostasis and lipid droplet formation in macrophages \[[@CR97]\]. Whether altered cholesterol metabolism contributes to the augmented "inflammatory response" observed following treatment of LPS in activated microglia with 25-HC remains to be determined. Nugent et al. recently reported that CH25H is one of the genes induced by demyelination partially in an apoE-dependent manner \[[@CR29]\]. Interestingly, 25-HC was also previously reported to increase the secretion of apoE by HepG2 cells, likely by upregulation of apoE mRNA \[[@CR98]\]. These observations indicate a potential interaction between 25-HC and apoE expression/secretion, which needs to be further investigated.

25-HC, IL-1β production, and inflammasome activation {#Sec23}
----------------------------------------------------

Consistent with the work of Jang et al. \[[@CR82]\], we provide evidence supporting a pro-inflammatory role of 25-HC in microglia by promoting mature 17kD IL-1β production via inflammasome activation. However, we did not observe any change of pro-IL-1β mRNA or protein levels in 25-HC treated microglia, suggesting that 25-HC augments cytokine production via a posttranslational mechanism. The induction of IL-1β production is dependent on two signals: first, activation of TLR4 on the cell surface by stimuli such as LPS leading to IL-1β mRNA generation and pro-IL-1β production. A second process derives from inflammasome activation by stimuli such as ATP, which leads to activation of caspase-1, a protease that cleaves pro-IL-1β into mature IL-1β. We found that 25-HC efficiently amplifies IL-1β production in the presence of LPS; however, 25-HC does not activate IL-1β production by itself at either the mRNA or protein level. These observations suggest that 25-HC might act as a second activation signal in microglia and directly or indirectly activate inflammasome activity upstream of caspase-1 (shown in Supplementary Fig. [3](#MOESM1){ref-type="media"}). In fact, we observed markedly reduced IL-1β production when 25-HC and LPS were coincubated in the presence of the caspase-1 inhibitor VX765 or when K+ efflux was blocked by high concentrations of extracellular K+. Again, these data suggest that augmentation of inflammasome activity and IL-1β production by 25-HC occurs post-translationally upstream of K+ efflux. It remains to be further determined if 25-HC augments IL-1β production via activation of NLRP3 or another inflammasome.

Our observations, together with Jang et al. \[[@CR82]\], are not consistent with the previous report by Reboldi et al. \[[@CR99]\]. In activated BMDMs, they found that low concentrations of 25-HC inhibited IL-1β production and that CH25H deficiency caused augmented transcription and secretion of the cytokine IL-1β. They also showed that 25-HC regulates IL-1β production via repressing SREBP-mediated transcription \[[@CR99]\]. Following this, Dang et al. later showed that up-regulating CH25H and 25-HC production reduce inflammasome activity and IL-1β levels in LPS-activated macrophages \[[@CR100]\]. The discrepancy between the results of Reboldi et al. \[[@CR99]\] and our data may be due to differences in treatment conditions (such as LPS or 25HC concentrations, treatment duration time, etc.) and the different cell types used in our respective experiments. In our study, we used a relatively high concentration of 25-HC to see whether we could rescue the CH25H knockout microglial phenotype. We wanted to make sure that we had adequate extracellular, but importantly intracellular, concentrations of 25-HC. It is important to appreciate that this concentration of 25-HC, however, did not by itself stimulate IL-1β or IL-1α expression/secretion from microglia in the absence of co-treatment with LPS. We would also underscore that the effects of 25-HC in potentiating IL-1β/α expression/secretion in microglia are also observed at much lower concentrations (e.g., 1 μg/ml see Fig. [5](#Fig5){ref-type="fig"}d) as well as reported by Rosklint et al. in human macrophages \[[@CR79]\]. Moreover, the effects of 25-HC are stereospecific in that ent-25-HC (the inactive enantiomer of 25-HC) is relatively inactive in amplifying IL-1β secretion even at the same high concentration of 25-HC used in our rescue experiments (see Fig. [5](#Fig5){ref-type="fig"}d).

Conclusion {#Sec24}
==========

With advances in genomic sequencing and bioinformatics, more genetic risk factors and related molecular pathways have been identified as potentially important in the etiology and pathogenesis of AD. These risk genes associated with late-onset AD point to both changes in lipid metabolism and immune mechanisms as contributing to AD pathology. However, exactly how the components of these distinct essential cellular pathways contribute to the progressive neurodegeneration in AD remains unclear. Our present study has identified an interaction among APOE genotype, cholesterol metabolism to the oxysterol 25-HC and the cytokine IL-1β in microglia. Our data suggest that microglial expression and activation of the enzyme CH25H and consequent 25-HC production may be an important mediator of the progressive neuroinflammation that characterizes neurodegenerative disorders like AD. Importantly, the pro-inflammatory effects of 25-HC we observe in primary microglia are APOE isoform-dependent, as apoE4-expressing microglia secrete more 25-HC and are markedly more sensitive to the pro-inflammatory actions of 25-HC than apoE2 or apoE3-expressing microglia. Thus, the immune oxysterol 25-HC may play an important role in the pathogenesis, i.e., the neuroinflammation and neurodegeneration, that characterize AD and perhaps other neurodegenerative disorders.
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**Additional file 1: Figure S1.** a). Expression of CH25H, Cyp27a1 and Cyp7b1 in different cell types in brain based on the Stanford transcriptome database generated by Barres and colleagues (<http://www.brainrnaseq.org>). b). GC-MS analysis of 25-HC levels in the conditioned medium (left) and total protein levels of cell lysate of primary mouse microglia from wild-type and CH25H-/- mice treated with LPS (0, 0.1, 1, 10, 100, 1000ng/ml). **Figure S2a.** Differential expression of CH25H or its ortholog in a comparison within one of the datasets. Fold-Changes are relative to non-transgenic, untreated, normal, adult, cortical or parenchymal microglia as appropriate, or, for the last two comparisons, relative to non-myeloid CNS cells (Friedman, et al Cell Report, 2018) <http://researchpub.gene.com/BrainMyeloidLandscape>. **2b.** Relative CH25H gene expression in nonphagocytic (NP) and phagocytic (P) wild-type (WT) or apoe-/- (KO) microglia by RNA seq analysis data generated by Krasemann et al, (Immunity, 47:566, 2017). **Figure S3**. A schematic diagram for the mechanism associated with 25-HC in amplifying IL-1b production via inflammasome activation.
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